Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg vs Placebo as Adjuvant Treatment in Chronic Migraine -

Chronic Migraine, Headache Clinical Trial

— CAMTREA  

Official title:

Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day as Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04989413
• Other study ID #: HIAE CAMTREA Protocol
• Status: Recruiting
• Phase: Phase 4
• Start date: October 18, 2022
• Est. completion date: April 19, 2024

Study information

• Verified date: January 2023
• Source: Hospital Israelita Albert Einstein
• Contact: Fernanda Assir
• Phone: +55 11 21510724
• Email: fernanda.assir[@]einstein.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic migraine (CM) patients under preventive treatment at a stable dose for at least 3 months who present at least 5 headaches day a month. CM patients of both sexes, between 25 and 65 years old, who have not had CBD and/or THC as a migraine treatment. Patients may be having migraine preventive treatment such as propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A. Acute treatment will follow patients doctor's prescription. Exclusion criteria: active liver disease or elevated liver transaminases> 3 times than the normal values, pregnancy, fertile age women without contraceptive treatment or who intend to get pregnant, patients without migraine preventive treatment or that changed the preventive treatment less than 3 months from the study start, substance abuse or addiction, use of medical cannabis or products with CBD or THC in the last 30 days or during study period, history of allergy or adverse reactions with the use of CBD or related products, substance users of liver enzymes inducers such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus. Patients on vitamin K anticoagulant medicines, as warfarin. Randomization using a computacional system will stratify participants in each group by gender (F/M), age (25-34/35-44/45-54/55-65yo), headache days presented in the baseline month (5-10/11-15/16-20/21-25/26-30), overuse medication (yes or no). After randomization patients will be divided into two groups of 55 participants, who will receive CBD + CBG + THC up to a maximum daily dose of 133/66/4 mg or placebo for 12 weeks (V0 screening, V1 allocation, V4 final visit). The main outcome is the reduction in frequency of headache days per 4 weeks between V1 and V4 compared to placebo. Secondary outcomes will be a reduction in duration and intensity of migraine attacks, amount of painkillers used and percentage of patients with a reduction greater than 50% on migraine days, 50% reduction in the other variables as MIDAS scores, HIT-6 scores, Beck's Anxiety and Depression Scales, Epworth Sleepiness Scales, and the scores at The Severity of Dependence Scale used as an indicator of overuse medication in this sample. Clinical data will be registered on a personalized headache diary developed to this study using MyCap, from RedCap System, as an APP for daily entries using smartphones, androids or IOS system. The clinical and laboratory data obtained in this study will comply with the objectives elaborated in the evaluation of the primary and secondary endpoints, the proposal of which is to publish the data regardless of the results obtained.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: April 19, 2024
• Est. primary completion date: October 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients of both sexes, 25 to 65 years old, with chronic migraine according to IHS Classification System, 3rd edition
• Undergoing preventive treatment in a stable dose of the preventive medication for at least 2 months, who have not used cannabidiol to treat migraine.
• At least 5 days of migraine/migraine like attacks in the baseline period (4 weeks)
• As preventive drugs propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A will be allowed. Patients whose preventive treatment for migraine is Botulinum Toxin Type A may participate in the study as long as the toxin application interval used is 4 months (duration of medication or placebo use) and who have already received treatment with toxin at least 2 times.
• If acute treatment is necessary, patients may use the medications as previously advised by the physician accompanying them, and may use common, combined painkillers, anti-inflammatory drugs, triptans, triptans combined with anti-inflammatory drugs, opioid analgesics.

Exclusion Criteria:

• Patients with active liver disease
• pregnancy and/or women who intend to become pregnant or who do not make adequate use of contraceptive therapy/methods
• breastfeeding women
• use of cannabis during the study, whether with therapeutic or recreational intentions
• patients who are without preventive treatment or who have undergone a dose change in preventive migraine treatment less than two months before V1 .
• Patients whose exclusive treatment for chronic migraine is Botulinum Toxin Type A at intervals of less than 4 months.
• History of substance abuse or addiction, use of medical cannabis or products with CBD, CBG or THC in the last 30 days, history of allergy to CBD or related products
• elevated transaminases > 3x the normal value
• substance abusers
• patients using substances that are potent enzyme inducers, such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus.
• Patients using anticoagulant, like vitamin K anticoagulant medicines, as warfarin.

Related Conditions & MeSH terms

• Chronic Migraine, Headache
• Headache
• Migraine Disorders

Intervention

Drug:
• Placebo oral drops
use of placebo for 12 weeks
• Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg
use of cannabidiol + canabigerol + thc for 12 weeks

Locations

Country	Name	City	State
Brazil	Centro de Pesquisa Clinica Hospital Israelita Albert Einstein	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Israelita Albert Einstein	Industria Farmacêutica Health Meds

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Migraine days	The primary outcome will be the reduction in migraine days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo)	16 weeks
Secondary	Headache days	The primary outcome will be the reduction in headache days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	migraine duration	the attack duration in hours observed before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	migraine intensity	the migraine attack intensity measured in a 3 point scale (1- mild; 2 - moderate; 3 - severe) before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	pain medicine intake	the amount of pain medicine intake as needed before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	number of patients with migraine reduction greater than 50%	the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	number of patients with headache reduction greater than 50%	the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in MIDAS score	the observed change in MIDAS score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in HIT-6 score	the observed reduction in HIT-6 score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in Beck's Anxiety Inventory scores	the observed change in BAI score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in Beck's Depression Inventory scores	the observed change in BDI score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in Severity of Dependence Scale scores	the observed change in SDS score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks
Secondary	Change in Epworth Sleepiness Scale scores	the observed change in Epworth score, before and after the intervention (CBD+CBG+THC or placebo)	12 weeks